Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells

Add time:07/19/2019    Source:sciencedirect.com

Multidrug resistance (MDR) refers to the cross-resistance of cancer cells to one drug, accompanied by other drugs with different mechanisms and structures, which is one of the main obstacles of clinical chemotherapy. Overexpression of P-glycoprotein (P-gp) was an extensively studied cause of MDR. Therefore, inhibiting P-gp have become an important strategy to reverse MDR. In this study, two series of triazole-tetrahydroisoquinoline-core P-gp inhibitors were designed and synthesized. Among them, compound I-5 had a remarkable reversal activity of MDR activity and the preliminary mechanism study was also carried out. All the results proved that compound I-5 was considered as a promising P-gp-mediated MDR reversal candidate.

We also recommend Trading Suppliers and Manufacturers of (5-METHYL-2-PHENYL-2H-1,2,3-TRIAZOL-4-YL)METHANOL (cas 13322-19-5). Pls Click Website Link as below: cas 13322-19-5 suppliers

Prev:Studies on destruction of silicon tetrachloride using microwave plasma jet
Next:O,O-dialkylphosphoroselenoic acids as functionalising reagents of monosaccharides—III)